$1.61
0.63% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US69353Y1038
Symbol
PMVP

PMV Pharmaceuticals Inc Stock price

$1.61
+0.12 8.05% 1M
-0.55 25.46% 6M
-1.49 48.06% YTD
-0.80 33.20% 1Y
-22.18 93.23% 3Y
-16.39 91.06% 5Y
-16.39 91.06% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.01 0.63%
ISIN
US69353Y1038
Symbol
PMVP
Sector
Industry

Key metrics

Market capitalization $82.80m
Enterprise Value $-87.59m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.84
P/B ratio (TTM) P/B ratio 0.42
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-79.18m
Free Cash Flow (TTM) Free Cash Flow $-47.50m
Cash position $183.66m
EPS (TTM) EPS $-1.00
P/E forward negative
Short interest 1.93%
Show more

Is PMV Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

PMV Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a PMV Pharmaceuticals Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a PMV Pharmaceuticals Inc forecast:

Buy
100%

Financial data from PMV Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.46 1.46
51% 51%
-
-1.46 -1.46
51% 51%
-
- Selling and Administrative Expenses 20 20
18% 18%
-
- Research and Development Expense 57 57
0% 0%
-
-78 -78
5% 5%
-
- Depreciation and Amortization 1.46 1.46
51% 51%
-
EBIT (Operating Income) EBIT -79 -79
4% 4%
-
Net Profit -51 -51
29% 29%
-

In millions USD.

Don't miss a Thing! We will send you all news about PMV Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PMV Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
6 months ago
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma's rezatapopt, a first-in-class, investigational therapy for patients with loc...
Neutral
Business Wire
6 months ago
BOSTON & PRINCETON, N.J.--(BUSINESS WIRE)--Foundation Medicine and PMV Pharma partner to develop FoundationOne®CDx as a companion diagnostic for PMV Pharma's rezatapopt.

Company Profile

PMV Pharmaceuticals, Inc. engages in the development of p53 targeted small molecule drugs for the treatment of cancer. It combines unique biological understanding with pharmaceutical development focus. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in 2013 and is headquartered in New Jersey, NY.

Head office United States
CEO David Mack
Employees 63
Founded 2013
Website www.pmvpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today